patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L1 - TMB>10Mb, nivolumab plus ipilimumab versus platinum association, meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 progression or deaths (PFS) 0.58 [0.41, 0.82]< 1 0% 1 study (1/-) 99.9 % NA not evaluable important - objective responses (ORR) 2.26 [1.39, 3.66]> 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - safety endpoints 00 STRAE (any grade) 2.67 [1.51, 4.74]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - STRAE (grade 3-4) 2.19 [1.14, 4.20]< 1 0% 1 study (1/-) 0.9 % NA not evaluable non important - TRAE (any grade) 1.28 [0.71, 2.30]< 1 0% 1 study (1/-) 21.0 % NA not evaluable non important - TRAE (grade 3-4) 1.02 [0.64, 1.65]< 1 0% 1 study (1/-) 46.1 % NA not evaluable non important - TRAE leading to discontinuation (any grade) 3.49 [1.78, 6.83]< 1 0% 1 study (1/-) 0.0 % NA not evaluable non important - TRAE leading to discontinuation (grade 3-4) 2.90 [1.32, 6.37]< 1 0% 1 study (1/-) 0.4 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Anaemia TRAE (grade 3-4) 0.26 [0.07, 0.92]< 1 0% 1 study (1/-) 98.2 % NA not evaluable non important - Asthenia TRAE (grade 3-4) 1.18 [0.23, 5.95]< 1 0% 1 study (1/-) 42.0 % NA not evaluable non important - Constipation TRAE (grade 3-4) 0.59 [0.02, 17.65]< 1 0% 1 study (1/-) 61.9 % NA not evaluable non important - Decreased appetite TRAE (grade 3-4) 0.29 [0.03, 2.62]< 1 0% 1 study (1/-) 86.4 % NA not evaluable non important - Diarrhoea TRAE (grade 3-4) 1.78 [0.29, 10.84]< 1 0% 1 study (1/-) 26.6 % NA not evaluable non important - Fatigue TRAE (grade 3-4) 0.29 [0.03, 2.62]< 1 0% 1 study (1/-) 86.4 % NA not evaluable non important - Hypothyroidism TRAE (grade 3-4) 1.18 [0.02, 59.79]< 1 0% 1 study (1/-) 46.8 % NA not evaluable non important - Nausea TRAE (grade 3-4) 1.18 [0.16, 8.49]< 1 0% 1 study (1/-) 43.5 % NA not evaluable non important - Neutropenia TRAE (grade 3-4) 0.03 [0.00, 0.46]< 1 0% 1 study (1/-) 99.3 % NA not evaluable non important - Pruritus TRAE (grade 3-4) 4.77 [0.21, 106.62]< 1 0% 1 study (1/-) 16.5 % NA not evaluable non important - Rash TRAE (grade 3-4) 7.20 [0.36, 145.12]< 1 0% 1 study (1/-) 10.1 % NA not evaluable non important - Vomiting TRAE (grade 3-4) 0.19 [0.02, 1.60]< 1 0% 1 study (1/-) 93.5 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.